Abstract: Management of an extensive code database having multiple user tenants building code is provided. A request to check-in code is received, and a build and validation to check-in the update to a user's code is performed. The validation results in indication of an error due to a bad state of the system that performed the build. The build machine is rebooted, and a second build is performed. Optionally, a user is prompted during a grace time period to cancel the corrective action of rebooting the build machine. Optionally, the validation error may be indicated as a product issue, a network issue, or a known limitation in the compiler. Optionally, other corrective actions such as preventing retrying the build and escalating the error may be taken. Optionally, the build may be prevented when the check-in includes code that produced an error on a previous build.

Abstract: Cross-machine build scheduling of a codebase is provided. Systems, methods and computer-readable devices provide for breaking a monolithic codebase into a plurality of tenants. A file containing entries associated with one of the tenants is read, and a selected entry in the file is examined to determine if the entry is requesting the execution of parallel loop. If so, each loop of the parallel loops is executed in parallel, and the selected entry in the file is examined to determine if the entry is an independent loop. If so, the independent loop is executed, and the selected entry in the file is examined to determine if the entry is a dependent loop. If so, execution of the dependent loop is held.

Abstract: Management of a monolithic code is provided. A request to check-in a first code into a first tenant code of the monolithic code may be received. In response to receiving the request to check-in the first code, a first build of the first tenant code may be performed. A validation of the first build may be performed. Validation results may be provided.

Abstract: A method of treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (T&agr;1), an antiviral-effective amount of lamivudine, and optionally an antiviral-effective amount of famciclovir is disclosed.